Ping Zhang, Qing Zhang, Xinya Hu, Wei Chi, Weihua Yang
{"title":"Research Progress in Artificial Intelligence for Central Serous Chorioretinopathy: A Systematic Review.","authors":"Ping Zhang, Qing Zhang, Xinya Hu, Wei Chi, Weihua Yang","doi":"10.1007/s40123-025-01209-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This review synthesizes advancements in artificial intelligence (AI) applications for central serous chorioretinopathy (CSCR), analyzing challenges and outlining future research directions to guide personalized diagnostic and therapeutic strategies.</p><p><strong>Methods: </strong>A systematic literature search was conducted in the Web of Science database using a comprehensive AI-related keyword set (e.g., \"deep learning,\" \"neural networks,\" \"computer vision\") combined with \"central serous chorioretinopathy.\" The search yielded 698 records, with 73 original research studies selected after excluding reviews and non-empirical work based on predefined criteria.</p><p><strong>Results: </strong>The application of AI in CSCR has progressed from disease classification to dynamic prognostic prediction, leveraging multimodal data fusion (e.g., optical coherence tomography [OCT] and OCT angiography [OCTA] and fundus fluorescein angiography [FFA]) to enhance both qualitative and quantitative diagnostic accuracy. AI models outperform clinical experts in classifying retinal disease subtypes and segmenting lesions. However, clinical translation faces infrastructural barriers (e.g., incompatible PACS systems) and limited physician trust due to \"black box\" decision-making. New approaches, such as explainable AI (XAI), are being integrated to enhance the transparency and clinical applicability of AI models. Key limitations involve single-center data dependency, interobserver annotation variability, and the inability of static frameworks to capture dynamic lesion progression.</p><p><strong>Conclusion: </strong>AI enhances CSCR diagnosis and subtyping efficiency. To optimize clinical translation, future research should focus on multicenter data integration, dynamic visualization frameworks, and standardized guidelines, promoting interdisciplinary collaboration and prospective trials for personalized treatment strategies. Incorporating federated learning for privacy-preserving data sharing and prioritizing explainability will be essential to overcoming barriers to physician adoption and improving trust in AI-driven clinical decision-making. Future efforts should focus on creating dynamic systems that provide real-time insights into lesion progression and integrating them with standardized protocols for wider clinical adoption.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40123-025-01209-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This review synthesizes advancements in artificial intelligence (AI) applications for central serous chorioretinopathy (CSCR), analyzing challenges and outlining future research directions to guide personalized diagnostic and therapeutic strategies.
Methods: A systematic literature search was conducted in the Web of Science database using a comprehensive AI-related keyword set (e.g., "deep learning," "neural networks," "computer vision") combined with "central serous chorioretinopathy." The search yielded 698 records, with 73 original research studies selected after excluding reviews and non-empirical work based on predefined criteria.
Results: The application of AI in CSCR has progressed from disease classification to dynamic prognostic prediction, leveraging multimodal data fusion (e.g., optical coherence tomography [OCT] and OCT angiography [OCTA] and fundus fluorescein angiography [FFA]) to enhance both qualitative and quantitative diagnostic accuracy. AI models outperform clinical experts in classifying retinal disease subtypes and segmenting lesions. However, clinical translation faces infrastructural barriers (e.g., incompatible PACS systems) and limited physician trust due to "black box" decision-making. New approaches, such as explainable AI (XAI), are being integrated to enhance the transparency and clinical applicability of AI models. Key limitations involve single-center data dependency, interobserver annotation variability, and the inability of static frameworks to capture dynamic lesion progression.
Conclusion: AI enhances CSCR diagnosis and subtyping efficiency. To optimize clinical translation, future research should focus on multicenter data integration, dynamic visualization frameworks, and standardized guidelines, promoting interdisciplinary collaboration and prospective trials for personalized treatment strategies. Incorporating federated learning for privacy-preserving data sharing and prioritizing explainability will be essential to overcoming barriers to physician adoption and improving trust in AI-driven clinical decision-making. Future efforts should focus on creating dynamic systems that provide real-time insights into lesion progression and integrating them with standardized protocols for wider clinical adoption.
本文综述了人工智能（AI）在中枢性浆液性脉络膜视网膜病变（CSCR）中的应用进展，分析了面临的挑战并概述了未来的研究方向，以指导个性化的诊断和治疗策略。方法：利用人工智能相关的综合关键词集（如“深度学习”、“神经网络”、“计算机视觉”）结合“中枢浆液性脉络膜视网膜病变”，在Web of Science数据库中进行系统的文献检索。搜索产生了698条记录，在排除了基于预定义标准的评论和非实证工作后，选择了73项原创研究。结果：人工智能在CSCR中的应用已经从疾病分类发展到动态预后预测，利用多模式数据融合（如光学相干断层扫描[OCT]、OCT血管造影[OCTA]和眼底荧光素血管造影[FFA]）提高定性和定量诊断准确性。人工智能模型在视网膜疾病亚型分类和病变分割方面优于临床专家。然而，临床翻译面临着基础设施障碍（例如，不兼容的PACS系统）和由于“黑箱”决策导致的医生信任有限。可解释人工智能（XAI）等新方法正在被整合，以提高人工智能模型的透明度和临床适用性。主要的限制包括单中心数据依赖性、观察者间注释的可变性以及静态框架无法捕捉动态病变进展。结论：人工智能提高了CSCR的诊断和分型效率。为了优化临床翻译，未来的研究应侧重于多中心数据集成、动态可视化框架和标准化指南，促进跨学科合作和个性化治疗策略的前瞻性试验。将联邦学习纳入保护隐私的数据共享和优先考虑可解释性，对于克服医生采用人工智能的障碍和提高对人工智能驱动的临床决策的信任至关重要。未来的努力应该集中在创建动态系统，提供对病变进展的实时洞察，并将其与更广泛的临床应用的标准化方案相结合。
期刊介绍：
Aims and Scope
Ophthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from preclinical, clinical (all phases), observational, real-world, and health outcomes research around the use of ophthalmological therapies, devices, and surgical techniques.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Ophthalmology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.
Rapid Publication
The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of ophthalmic therapies.
Open Access
All articles published by Ophthalmology and Therapy are open access.
Personal Service
The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research.
Digital Features and Plain Language Summaries
Ophthalmology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’.
For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/
Publication Fees
Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis.
Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.
At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor.
Preprints
We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website.
Please follow the link for further information on preprint sharing:
https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550
Copyright
Ophthalmology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.
Contact
For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
